{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:50:24Z","timestamp":1793314224066,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":49,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ctrv.2022.102375","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T05:26:43Z","timestamp":1646371603000},"page":"102375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":303,"special_numbering":"C","title":["Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality"],"prefix":"10.1016","volume":"105","author":[{"given":"Amanda J.","family":"Kerr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McGale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Duane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep","family":"Mannu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2022.102375_b0005","doi-asserted-by":"crossref","first-page":"g5630","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2022.102375_b0010","unstructured":"Centre for Evidence-based Medicine. Centre for Evidence-based medicine \u2013 Levels of evidence. https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/ 2009 [accessed 22 Aug 2019]."},{"key":"10.1016\/j.ctrv.2022.102375_b0015","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011b;378:1707-16. https:\/\/doi.org\/10.1016\/S0140-6736(11)61629-2.","DOI":"10.1016\/S0140-6736(11)61629-2"},{"key":"10.1016\/j.ctrv.2022.102375_b0020","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44. https:\/\/doi.org\/10.1016\/S0140-6736(11)61625-5.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"10.1016\/j.ctrv.2022.102375_b0025","unstructured":"PREDICT, 2017. https:\/\/breast.predict.nhs.uk\/ [accessed 22 Aug 2019]."},{"key":"10.1016\/j.ctrv.2022.102375_b0030","unstructured":"Cancermath.net. http:\/\/www.lifemath.net\/cancer\/2019 [accessed 22 Aug 2019]."},{"key":"10.1016\/j.ctrv.2022.102375_b0035","unstructured":"National Institute for Health and Care Excellence (NICE). Early and locally advanced breast cancer: diagnosis and management 2018 (NICE Clinical Guideline ng101). https:\/\/www.nice.org.uk\/guidance\/ng101\/chapter\/Recommendations#adjuvant-chemotherapy-for-invasive-breast-cancer 2019 [accessed 22 Aug 2019]."},{"key":"10.1016\/j.ctrv.2022.102375_b0040","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.prro.2016.08.009","article-title":"Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update","volume":"6","author":"Recht","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prro.2016.09.007","article-title":"Accelerated Partial Breast Irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement","volume":"7","author":"Correa","year":"2017","journal-title":"Practical Radiation Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0055","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.breast.2021.12.003","article-title":"A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer","volume":"61","author":"Zhao","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2022.102375_b0065","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.breast.2015.12.007","article-title":"A systematic review of decision aids for patients making a decision about treatment for early breast cancer","volume":"26","author":"Zdenkowski","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.ctrv.2022.102375_b0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12913-019-3988-2","article-title":"Communicating prognosis to women with early breast cancer \u2013 overview of prediction tools and the development and pilot testing of a decision aid","volume":"19","author":"M\u00fchlbauer","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.ctrv.2022.102375_b0075","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ijrobp.2015.07.2292","article-title":"Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013","volume":"93","author":"Taylor","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102375_b0080","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-35. https:\/\/doi.org\/10.1016\/S0140-6736(14)60488-8.","DOI":"10.1016\/S0140-6736(14)60488-8"},{"key":"10.1016\/j.ctrv.2022.102375_b0085","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102375_b0095","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.radonc.2020.07.022","article-title":"Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer","volume":"151","author":"Journy","year":"2020","journal-title":"Radioth Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0100","first-page":"148","article-title":"Exposure of the lungs in breast cancer radiotherapy: A systematic review of lung doses published 2010\u20132015","volume":"126","author":"Aznar","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102375_b0105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.radonc.2021.09.032","article-title":"Exposure of the oesophagus in breast cancer radiotherapy: A systematic review of oesophagus doses published 2010\u20132020","volume":"164","author":"Duane","year":"2021","journal-title":"Radioth Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0110","unstructured":"National Cancer Institute. NCI Dictionary of Cancer Terms https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms [accessed 22 Oct 2019]."},{"key":"10.1016\/j.ctrv.2022.102375_b0115","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ctrv.2022.102375_b0120","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.2016.68.8879","article-title":"Can Observational Data Replace Randomized Trials?","volume":"34","author":"McGale","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0125","unstructured":"National Comprehensive Cancer Network Guidelines Version 2.2022 Breast Cancer. https:\/\/www.nccn.org\/ [accessed 4th Feb 2022]."},{"key":"10.1016\/j.ctrv.2022.102375_b0130","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1200\/JCO.2018.78.8604","article-title":"Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update","volume":"36","author":"Denduluri","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0135","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2022.102375_b0140","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/JCO.21.02677","article-title":"Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Expert Panel. Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0150","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0155","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customising local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0160","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","article-title":"Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019","volume":"30","author":"Burstein","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0165","unstructured":"NICE Technology Appraisal Guidance TA569, 2019. Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. https:\/\/www.nice.org.uk\/guidance\/ta569 [accessed 7th Nov 2020]."},{"key":"10.1016\/j.ctrv.2022.102375_b0170","unstructured":"NICE Technology Appraisal Guidance TA612, 2019. Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab. https:\/\/www.nice.org.uk\/guidance\/ta612 [accessed 7th Nov 2020]."},{"key":"10.1016\/j.ctrv.2022.102375_b0175","unstructured":"NICE Technology Appraisal Guidance TA632. Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer. 2020. https:\/\/www.nice.org.uk\/guidance\/ta632 [accessed 7th Nov 2020]."},{"key":"10.1016\/j.ctrv.2022.102375_b0180","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","article-title":"Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis","volume":"29","author":"Poggio","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0185","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2022.102375_b0190","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. https:\/\/doi.org\/10.1016\/S1470-2045(21)00288-6.","DOI":"10.1016\/S1470-2045(21)00288-6"},{"key":"10.1016\/j.ctrv.2022.102375_b0195","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2022.102375_b0200","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2022.102375_b0205","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0210","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Neo-adjuvant versus adjuvant chemotherapy in early breast cancer: long-term outcomes among 4756 women in 10 randomised trials. Lancet Oncol 2018;19: 27-39. https:\/\/doi.org\/10.1016\/S1470-2045(17)30777-5.","DOI":"10.1016\/S1470-2045(17)30777-5"},{"key":"10.1016\/j.ctrv.2022.102375_b0215","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011a;378:771-84. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8.","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"10.1016\/j.ctrv.2022.102375_b0220","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12032-017-0986-2","article-title":"Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials","volume":"34","author":"Ibrahim","year":"2017","journal-title":"Med Onc"},{"key":"10.1016\/j.ctrv.2022.102375_b0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ctrv.2022.102375_b0230","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Aromatase inhibitors versus tamoxifen in premenopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: patient-level meta-analysis of 7,030 women in four randomised trials. Lancet Oncol 2022 https:\/\/org\/10.1016\/S1470-2045(21)00758-0."},{"key":"10.1016\/j.ctrv.2022.102375_b0235","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015a;386:1341-52. https:\/\/doi.org\/10.1016\/S0140-6736(15)61074-1.","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"10.1016\/j.ctrv.2022.102375_b0240","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/annonc\/mdm566","article-title":"Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17","volume":"19","author":"Ingle","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years","volume":"375","author":"Goss","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2022.102375_b0250","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","article-title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Mamounas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0255","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015b;386:1353-61. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"10.1016\/j.ctrv.2022.102375_b0260","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)32514-0","article-title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial","volume":"394","author":"Vicini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2022.102375_b0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1470-2045(14)71156-8","article-title":"Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial","volume":"16","author":"Bartelink","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0270","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(20)30472-1","article-title":"Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922\/10925): 15-year results of a randomised, phase 3 trial","volume":"21","author":"Poortmans","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0275","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2022.102375_b0280","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2013.31.18_suppl.5","article-title":"aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer","volume":"31","author":"Gray","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102375_b0285","doi-asserted-by":"crossref","first-page":"e819","DOI":"10.1016\/j.clbc.2018.05.010","article-title":"A Systematic Review of Heart Dose in Breast Radiotherapy","volume":"18","author":"Drost","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2022.102375_b0290","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. Abstract GS2-06: Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials. Cancer Res 2022:82; G2-06. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-GS2-06.","DOI":"10.1158\/1538-7445.SABCS21-GS2-06"},{"key":"10.1016\/j.ctrv.2022.102375_b0295","unstructured":"Collins R, \u201cBig Data, Better Treatment\u201d: The work of the Early Breast Cancer Trialists' Collaborative Group. Available from: https:\/\/slideplayer.com\/slide\/8910693\/ [accessed: 12 May 2020]."}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:06Z","timestamp":1759656426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":59,"alternative-id":["S0305737222000391"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102375","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102375"}}